Table 5 Univariate and multivariate analyses concerning overall survival

Univariate analysis

Initial PS

1.53

0.93–2.50

0.08

Primary

Kidney vs lung

1.11

0.38–3.27

0.84

Other vs lung

3.68

1.01–13.35

0.047

Colorectal vs lung

8.28

0.80–84.95

0.075

Mutations Mol.Biol

KRAS vs no mutation

0.22

0.06–0.80

0.02

EGFR vs no mutation

0.5

0.10–2.53

0.4

HER2 vs no mutation

0.27

0.03–2.32

0.23

Extracranial metastasis at diagnosis

0.03

No

1

Yes

2.3

1.06–4.96

Brain metastasis as first sign of cxancer

0.8

No

1

Yes

0.91

0.44–1.88

Number of initial brain metastases

1.41

0.94–2.14

0.096

Previous GK treatment

0.44

0.06–3.31

0.43

Previous WBRT tretament

0.76

0.17–3.21

0.7

BSBM

0.48

0.31–0.73

0.001

GPA

0.47

0.28–0.78

0.004

RPA

2.05

0.86–4.87

0.1

Age at time of treatment

0.97

0.93–1.02

0.31

Subtentorial location

1

0.39

Supratentorial location

1.44

0.61–3.37

Size of preoperative lesion

2.55

1.02–6.40

0.046

Time between surgery-GK

0.98

0.96–1.00

0.06

Volume of lesion treated with GK

0.98

0.93–1.04

0.68

Dose GK treatment

1.03

0.88–1.21

0.67

Other existing lesions treatedat the same time withGK moment du GK

1.15

0.87–1.50

0.3

Multivariate analysis taking variables with p < 0.2 in univariate analysis

Initial PS

5.4

1.11–26.31

0.037

Nb of brain metastasis at diagnosis

2.72

1.004–7.36

0.049

Kras Mutation vs no mutation

0.066

0.007–0.66

0.021

EGFR Mutation no de mutation

6.99

0.52–93.18

0.14

HER2 Mutation no de mutation

1.88

0.11–31.56

0.65

BSBM

0.53

0.79–3.59

0.51

GPA

1.52

0.16–13.78

0.7

Delay between surgery -GK

0.97

0.93–1.01

0.23

Extra brain metastasis at diagnosis

0.6

0.1–3.62

0.58